尚榮醫療(002551.SZ):康力骨科擬以增發股權為對價收購吉美瑞87.2617%股份
格隆匯12月11日丨尚榮醫療(002551.SZ)公佈,公司直接持有吉美瑞19.2445%的股權,公司子公司錦洲醫械持有其68.0172%的股權,2020年12月11日,公司、錦洲醫械與康力骨科簽署了《蘇州市康力骨科器械有限公司與蘇州吉美瑞醫療器械股份有限公司股東之增發股權購買資產協議》,約定康力骨科擬以向錦洲醫械及尚榮醫療增發19.1976%的股權作為對價收購吉美瑞合計87.2617%的股份。
本次交易完成後,錦洲醫械將持有康力骨科14.9638%的股權、公司將持有康力骨科4.2338%的股權。康力骨科的評估值為7.3億元,吉美瑞87.2617%股份及對價股權本次交易的交易對價為1.81億元。
康力骨科是集研發、設計、製造、銷售骨科耗材的企業,該公司擁有超過三十項產品專利,公司致力於為患者、醫生及相關人士提供“互聯網+3D打印+精準醫療”融合的智能化、專業化、系統化解決方案,體系建設完善,具有較強的研發團隊和銷售團隊。本次交易完成後,吉美瑞將由康力骨科進行統一經營管理,有利於吉美瑞調整產品結構,提高產品質量,拓展銷售渠道,進一步完善和豐富吉美瑞的產品體系和產業鏈條,提高吉美瑞的運營效率和保障能力。與此同時,可降低康力骨科的運營成本,實現其高中低檔產品差異化銷售的目標。本次交易完成後,可提升交易雙方市場競爭力,實現交易各方雙贏的局面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.